Cost Effectiveness Kemoterapi Kombinasi Neoadjuvant Cisplatin - Paclitaxel Dibanding Cisplatin 5 Flourourasil Terhadap Respon Klinis pada Karsinoma Nasofaring

Authors

  • Dwi Antono
  • Muyassaroh Muyassaroh
  • Alfian Sulaksana

DOI:

https://doi.org/10.36408/mhjcm.v3i1.204

Abstract

Latar belakang : Cisplatin merupakan regimen obat sitostatika pilihan pada karsinoma nasofaring. Kemoterapi kombinasi neoadjuvant menghasilkan angka respon lebih tinggi pada KNF stadium lanjut. Tujuan penelitian ini adalah mengetahui cost effectiveness kemoterapi kombinasi neoadjuvant cis-pac dibanding cis-5FU terhadap respon klinis pada KNF. Metode : Penelitian deskriptif analitik rekam medik penderita KNF yang mendapatkan 3 siklus kemoterapi kombinasi neoadjuvant cis  pac atau cis - 5 FU di RSUP Dr. Kariadi Semarang periode Juni 2010 - Juli 2013. Analisis dengan uji Chi Square dan Average Cost Effectiveness Ratio (ACER). Hasil : Didapatkan 45 sampel, 25 mendapat kemoterapi kombinasi neoadjuvant cis-pac dan 20 mendapatkan kemoterapi kombinasi neoadjuvant cis-5FU. Respon klinis kemoterapi kombinasi neoadjuvant cis-pac respon positif (65,7%) dan respon negatif (20%) lebih baik dibanding kemoterapi kombinasi neoadjuvant cis5FU respon positif (34,3%) dan respon negatif (80%) (RP 1,533 dan 95% CI 1,05-2,233). Biaya kemoterapi kombinasi cis-pac lebih murah (86,7%) dibanding kemoterapi kombinasi cis-5FU (13,3%) (RP 5,200 dan 95% CI 1,324-20,416). ACER total biaya kemoterapi kombinasi cis-pac lebih cost effective (190.325,6) dibanding kemoterapi kombinasi cis-5FU (290.604,7). Simpulan : Respon klinis kemoterapi kombinasi neoadjuvant cispac lebih baik dibanding kemoterapi kombinasi neoadjuvant cis5FU. Pemberian kemoterapi kombinasi neoadjuvant cis-pac lebih cost effective dibanding kemoterapi kombinasi neoadjuvant cis5FU.

Downloads

Download data is not yet available.

Additional Files

Published

2017-09-16

How to Cite

1.
Antono D, Muyassaroh M, Sulaksana A. Cost Effectiveness Kemoterapi Kombinasi Neoadjuvant Cisplatin - Paclitaxel Dibanding Cisplatin 5 Flourourasil Terhadap Respon Klinis pada Karsinoma Nasofaring. Medica Hospitalia J. Clin. Med. [Internet]. 2017 Sep. 16 [cited 2024 Apr. 20];3(1). Available from: http://medicahospitalia.rskariadi.co.id/medicahospitalia/index.php/mh/article/view/204

Issue

Vol. 3 No. 1 (2015): Med Hosp; Mei 2015

Section

Original Article

Citation Check

License

Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.